Work

Microbials for the production of monoclonal antibodies and antibody fragments

Year: 2013

Type: review

Abstract: Monoclonal antibodies (mAbs) and antibody fragments represent the most important biopharmaceutical products today. Because full length antibodies are glycosylated, mammalian cells, which allow human-like N-glycosylation, are currently used for their production. However, mammalian cells have several drawbacks when it comes to bioprocessing and scale-up, resulting in long processing times and elevated costs. By contrast, antibody fragments, that are not glycosylated but still exhibit antigen binding properties, can be produced in microbial organisms, which are easy to manipulate and cultivate. In this review, we summarize recent advances in the expression systems, strain engineering, and production processes for the three main microbials used in antibody and antibody fragment production, namely Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli.

Source: Trends in biotechnology

DOI: 10.1016/j.tibtech.2013.10.002

Authors: Oliver Spadiut, Simona Capone, Florian Krainer, Anton Glieder, Christoph Herwig

Institutions: TU Wien, Graz University of Technology, Austrian Centre of Industrial Biotechnology (Austria)

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

Open Access status: hybrid

Estimated APC paid: $2,939

Funder: Austrian Science Fund